Login to Your Account

Vion's $32M Stock Offering Will Fund Cloretazine Phase III Trial

By Randall Osborne

Thursday, January 27, 2005
About two weeks after its shelf registration became effective, Vion Pharmaceuticals Inc. has agreed to sell up to 10 million shares in a direct offering at $3.25 each to institutional investors, with net proceeds of about $30 million after placement fees and other expenses are paid. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription